Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer

Area of Science:

• Oncology
• Endocrinology
• Medical Diagnostics

Background:

• Differentiated thyroid cancer (DTC) generally has an excellent prognosis.
• Overtreatment is common due to challenges in identifying aggressive disease subtypes.
• Accurate risk stratification is crucial for personalized treatment strategies.

Purpose of the Study:

• To identify key prognostic factors for predicting treatment response in DTC patients.
• To explore novel markers beyond traditional risk stratification systems.
• To optimize treatment strategies by distinguishing high-risk from low-risk patient cohorts.

Main Methods:

• Review of common prognostic factors (age, tumor size, grade, invasion, metastases).
• Analysis of emerging markers: histology, multifocality, Radioiodine Therapy (RAI) details, Thyroglobulin (Tg), Anti-thyroglobulin Antibodies (Tg-Ab), benign thyroid disease.
• Evaluation of remnant size/avidity and surgeon experience's impact on recurrence and prognosis.

Main Results:

• Treatment response is significantly associated with histology, T and M stages, and surgeon experience.
• Thyroglobulin (Tg) levels and remnant score during RAI and follow-up are key indicators.
• Anti-thyroglobulin Antibody (Tg-Ab) levels during follow-up whole body scans (WBS) correlate with treatment response.

Conclusions:

• Histology, tumor stage, surgeon experience, Tg levels, remnant score, and Tg-Ab levels are critical for assessing DTC prognosis.
• Integrating these factors can refine risk stratification and personalize patient management.
• Improved prognostic accuracy can reduce overtreatment and enhance outcomes for high-risk DTC patients.